Evidence map›Paper›PMID 34870375›Full record

ReviewCancer medicine2022

Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression.

Ksenia S Maslyonkina, Alexandra K Konyukova, Darya Y Alexeeva, Mikhail Y Sinelnikov, Liudmila M Mikhaleva

Abstract readReview
In one paragraph

Review in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Barrett's Esophagus: An Updated Review.Diagnostics (Basel, Switzerland) · 2023
    Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ksenia S MaslyonkinaResearch Institute of Human Morphology, Moscow, Russian Federation.ORCID 0000-0001-8083-9428
Alexandra K KonyukovaResearch Institute of Human Morphology, Moscow, Russian Federation.
Darya Y AlexeevaResearch Institute of Human Morphology, Moscow, Russian Federation.
Mikhail Y SinelnikovResearch Institute of Human Morphology, Moscow, Russian Federation.ORCID 0000-0002-0862-6011
Liudmila M MikhalevaResearch Institute of Human Morphology, Moscow, Russian Federation.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Barrett's esophagus is a widespread chronically progressing disease of heterogeneous nature. A life threatening complication of this condition is neoplastic transformation, which is often overlooked due to lack of standardized approaches in diagnosis, preventative measures and treatment. In this essay, we aim to stratify existing data to show specific associations between neoplastic transformation and the underlying processes which predate cancerous transition. We discuss pathomorphological, genetic, epigenetic, molecular and immunohistochemical methods related to neoplasia detection on the basis of Barrett's esophagus. Our review sheds light on pathways of such neoplastic progression in the distal esophagus, providing valuable insight into progression assessment, preventative targets and treatment modalities. Our results suggest that molecular, genetic and epigenetic alterations in the esophagus arise earlier than cancerous transformation, meaning the discussed targets can help form preventative strategies in at-risk patient groups.

Indexed as

Epigenesis, GeneticAdenocarcinomaBarrett EsophagusBiomarkers, TumorCell Transformation, NeoplasticDisease ProgressionEsophageal NeoplasmsHumansPrecancerous ConditionsBiomarkers, TumorBarrett's esophagusepigenetic changesesophageal cancermolecular pathwaysoncotransformationpreventative targets

Identifiers

PMID34870375
PMCPMC8729054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.